SG11201808990QA - Compositions for topical application of compounds - Google Patents

Compositions for topical application of compounds

Info

Publication number
SG11201808990QA
SG11201808990QA SG11201808990QA SG11201808990QA SG11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA
Authority
SG
Singapore
Prior art keywords
international
compositions
pct
california
april
Prior art date
Application number
SG11201808990QA
Inventor
Jacob Waugh
Original Assignee
Illustris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Illustris Pharmaceuticals Inc filed Critical Illustris Pharmaceuticals Inc
Publication of SG11201808990QA publication Critical patent/SG11201808990QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/62—Coated
    • A61K2800/624—Coated by macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111111011101111111111101111101111011111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/180788 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 8/02 (2006.01) A61K 45/00 (2006.01) kind A61K 8/18 (2006.01) A61P 17/18 (2006.01) AO, A61K 8/19 (2006.01) A61Q 19/00 (2006.01) BZ, A61K 33/00 (2006.01) C07K 14/78 (2006.01) DO, A61K 38/00 (2006.01) HN, KP, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/US2017/027275 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: RU, 12 April 2017 (12.04.2017) TH, ZA, ZM, ZW. RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, 62/321,626 12 April 2016 (12.04.2016) US TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: ILLUSTRIS PHARMACEUTICALS, INC. DK, [US/US]; 4030 Fabian Way, Unit B, Palo Alto, California LV, 94303 (US). SM, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventor: WAUGH, Jacob; 14 Point Loma Drive, Corona GW, KM, ML, MR, NE, SN, TD, TG). del Mar, California 92625 (US). Published: Agent: WADSWORTH, Curtis C.; Pepper Hamilton — with (74) international search report (Art. 21(3)) LLP, 500 Grant Street, Suite 5000, Pittsburgh, Pennsylvania 15219-2507 (US). 1-1 GC GC IN © GC 11 IN 11 © ei (54) Title: COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS C ) .,.. (57) : Compositions for transdermal delivery of an active agent and methods for using such compositions are described herein.
SG11201808990QA 2016-04-12 2017-04-12 Compositions for topical application of compounds SG11201808990QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321626P 2016-04-12 2016-04-12
PCT/US2017/027275 WO2017180788A1 (en) 2016-04-12 2017-04-12 Compositions for topical application of compounds

Publications (1)

Publication Number Publication Date
SG11201808990QA true SG11201808990QA (en) 2018-11-29

Family

ID=59999163

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808990QA SG11201808990QA (en) 2016-04-12 2017-04-12 Compositions for topical application of compounds

Country Status (11)

Country Link
US (2) US20170290778A1 (en)
EP (1) EP3442488A4 (en)
JP (1) JP2019513799A (en)
KR (1) KR20190022476A (en)
CN (1) CN109152702A (en)
AU (1) AU2017250267A1 (en)
CA (1) CA3020400A1 (en)
IL (1) IL262180A (en)
MX (1) MX2018012486A (en)
SG (1) SG11201808990QA (en)
WO (1) WO2017180788A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
KR20070110402A (en) * 2005-03-03 2007-11-16 레반스 테라퓨틱스 Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
MX344583B (en) 2009-06-25 2016-12-20 Revance Therapeutics Inc Albumin-free botulinum toxin formulations.
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
EP3432916B1 (en) 2016-09-13 2019-08-14 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
US11040090B2 (en) * 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
EP3694489A4 (en) * 2017-10-11 2021-06-30 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery
KR102189632B1 (en) * 2018-03-09 2020-12-11 전남대학교산학협력단 Novel fungus Penicillium acidum and use thereof
KR101899413B1 (en) 2018-05-03 2018-09-18 주식회사 케어사이드 Composition for prevention and treatment of skin infection
KR102088104B1 (en) * 2018-06-29 2020-03-11 호서대학교 산학협력단 Composition for preventing and treating of neuro muscular diseases comprising essential oil from Erigeron annuus
CN111825775B (en) * 2019-04-18 2021-11-02 复旦大学 Cupressus sempervirens polysaccharide, preparation method thereof and application thereof in preparing antitumor drugs
CN110090193B (en) * 2019-05-14 2022-04-12 东方爱堡(北京)母婴健康科技有限公司 Acne-removing moisturizing essence with fat-reducing effect and preparation method thereof
CN111110831B (en) * 2020-02-20 2023-08-08 柳州市工人医院 Ulcer paste and preparation method thereof
CN111297884B (en) * 2020-04-02 2021-03-30 中国农业科学院蜜蜂研究所 Application of adenosine in prevention and treatment of bee virus infection
CN111329846A (en) * 2020-04-24 2020-06-26 云南伦扬科技有限公司 Vaginal sterilization adhesive film and preparation method thereof
CN111587861A (en) * 2020-05-21 2020-08-28 广州市穗升有害生物防治中心 Luring box
CN114617974B (en) * 2020-12-10 2023-10-03 中国科学院苏州纳米技术与纳米仿生研究所 Polypeptide albumin nanoparticle and preparation method and application thereof
CN116847871A (en) * 2021-02-05 2023-10-03 现代牧场股份有限公司 Skin care compositions and methods of use
WO2022232161A1 (en) * 2021-04-26 2022-11-03 Sypherion, Llc Inhibitors of nsp1 for treatment of sars-cov-2
CN113332238A (en) * 2021-06-09 2021-09-03 四川恒通动保生物科技有限公司 Preparation method of compound solution with gamithromycin
JP7141025B1 (en) * 2021-11-11 2022-09-22 エルデシエロ プライベート リミテッド Compounds, compositions, methods, and methods of manufacture
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2024007014A2 (en) * 2022-06-30 2024-01-04 Board Of Trustees Of The University Of Arkansas Process for treating livestock exposed to toxic forage using melatonin compositions
CN116098882A (en) * 2023-04-06 2023-05-12 山东诚创蓝海医药科技有限公司 Composition containing lidocaine prilocaine and preparation method thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
IT1260148B (en) * 1992-04-17 1996-03-28 Fidia Spa USE OF HYALURONIC ACID PREPARATIONS FOR THE FORMATION OF BONE TISSUE
US8728510B1 (en) * 2002-03-15 2014-05-20 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing a bioadhesive material
US7956180B2 (en) * 2004-05-27 2011-06-07 Novozymes A/S Dried and agglomerated hyaluronic acid product
CA2589761A1 (en) * 2004-12-07 2006-06-15 Surmodics, Inc. Coatings with crystallized active agent(s) and methods
US7727537B2 (en) * 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
CA2624362C (en) * 2005-10-03 2015-05-26 Mark A. Pinsky Liposomes comprising collagen and their use in improved skin care
EP2120844B1 (en) * 2006-12-26 2016-11-16 Bomi Patel Framroze Skin lightening composition for hyperpigmented skin
WO2008124169A2 (en) * 2007-04-10 2008-10-16 The Trustees Of The University Of Pennsylvania Islet cells composition and methods
US20100008878A1 (en) * 2007-08-09 2010-01-14 Foodchemifa Co., Ltd Propylene glycol hyaluronate, and skincare preparation for external use comprising same
DE102008034265A1 (en) * 2008-07-22 2010-01-28 Beiersdorf Ag Active substance combination of aniseed extract and hyaluronic acid
JP5916388B2 (en) * 2008-11-14 2016-05-11 ヒストジェン インコーポレイテッド Extracellular matrix composition for the treatment of cancer
US8679470B2 (en) * 2008-11-28 2014-03-25 Luromed Llc Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications
EP2437755B1 (en) * 2009-05-19 2017-04-12 Plurogen Therapeutics, LLC Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing
EP2432495B1 (en) * 2009-05-20 2017-03-22 Humacyte, Inc. Elastin for soft tissue augmentation
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
US20110305737A1 (en) * 2010-06-09 2011-12-15 NY Derm LLC Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology
FR2971711B1 (en) * 2011-02-18 2014-06-13 Isp Investments Inc COSMETIC COMPOSITION COMPRISING A SMALL SPEECH EXTRACT AS AN ACTIVATOR OF THE EXTRACELLULAR MATRIX PROTEIN SYNTHESIS
WO2014134532A1 (en) * 2013-02-28 2014-09-04 Ventrix, Inc. Methods and compositions for tissue therapy and analysis
EP2961942B1 (en) * 2013-02-28 2020-07-08 United Technologies Corporation Method and apparatus for handling pre-diffuser airflow for cooling gas turbine components

Also Published As

Publication number Publication date
KR20190022476A (en) 2019-03-06
US20170290778A1 (en) 2017-10-12
JP2019513799A (en) 2019-05-30
AU2017250267A1 (en) 2018-11-08
WO2017180788A1 (en) 2017-10-19
CA3020400A1 (en) 2017-10-19
CN109152702A (en) 2019-01-04
MX2018012486A (en) 2019-06-06
US20190008795A1 (en) 2019-01-10
EP3442488A4 (en) 2020-03-25
IL262180A (en) 2018-11-29
EP3442488A1 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909949XA (en) Targeted immunotolerance
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908391XA (en) Methods for modulating an immune response
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907023UA (en) Method of reducing neutropenia
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201804704PA (en) Compositions and methods for decreasing tau expression